Review Article
Achieving Glycemic Control in Type 2 Diabetes: A Practical Guide for Clinicians on Oral Hypoglycemics
Abstract
Type 2 diabetes mellitus has reached epidemic proportions in the United States. Cardiovascular morbidity and mortality are particularly high in this patient population. Improved glucose control, especially early in the course of diabetes, can slow or prevent complications, preserve β-cell function, and improve long-term outcomes. Within the last decade, new treatments and glycemic goals have created an opportunity to better manage this prevalent, chronic disease. Defects of insulin resistance and deficiency leading to type 2 diabetes can now be directly targeted with available therapies. In addition to diet and exercise, oral treatment options have been broadened, with both insulin secretagogues and insulin sensitizers. These advances in treatment options make glycemic control an obtainable target, and therefore should improve overall morbidity and mortality for patients. This paper will review currently available oral therapies, with a focus on the unique attributes of the insulin sensitizers for patients with type 2 diabetes.
Key Points
* Type 2 diabetes mellitus is an epidemic with significant cardiovascular morbidity and mortality.
* New treatments and glycemic goals have allowed better therapeutic options for patients.
* Insulin sensitizers are safe, effective, and have benefits beyond glycemic control.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Centers for Disease Control and Prevention. CDC at a Glance: Diabetes; A Serious Public Health Problem. Atlanta, 2001.
2. Gerich J. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Pro 2003;78:447–56.
3. Albright E. The diabetes epidemic, Ala Diabetes Monitor 2002;1(1):1–2.
4. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-Year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med1998;128:165–175.
5. Nathan D. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med2002;347(17):1342–1349.
6. Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord2002;26(suppl 3):S25–S30.
7. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. J Am Med Assoc 2002;287(3):356–359.
8. National Institutes of Health. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda MD: National Institutes of Health;2001:NIH Publication 01–3670.
9. Haffner SM, Miettinen H, and Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia 1997;40(6):711–717.
10. Kirpichnikov D, McFarlane S, Sowers J. Metformin: an update. Ann Intern Med 2002;137(1):25–33.
11. McFarlane S, Banerji M, Sowers J. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86(2):713–718.
12. Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord 2002;26(suppl 3):S9–S17.
13. UKPDS Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405–412.
14. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.
15. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complication in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28(2):103–117.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–986.
17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus.Diabetes Care 2002;25(suppl 1):S33–S49.
18. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management–update 2002. Endocr Pract 2002;8(suppl 1):40–65.
19. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin N Am 2001;30:909–933.
20. Mahler R, Adler M. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment.J Clin Endocrinol Metab 1999;84:1165–1171.
21. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc2002;287:360–372.
22. Luna B, Feinglos M. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician2001;63:1747–1756.
23. Johnston P. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515–1522.
24. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
25. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol2002;90(5A):3G–10G.
26. Gugliucci A, Ghitescu L. Is diabetic hypercoagulability an acquired annezinopathy? Glycation of annexin II as a putative mechanism for impaired fibrinolysis in diabetic patients. Med Hypotheses2002;59:247–251.
27. Physician’s Desk Reference. Montvale, NJ, Medical Economics Company, 2001, ed 55, pp 1005–1009.
28. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491–497.
29. Pearlman B, Fenves A, Emmett M. Metformin-associated lactic acidosis. Am J Med 1996;101:109–110.
30. Calabrese A, Coley K, DaPos S. Risk of lactic acidosis with metformin therapy. Arch Intern Med2002;162:434–437.
31. Albright ES, Bell DSH. The liver, liver disease and diabetes. The Endocrinologist 2003;13(1):58–66.
32. Gilliagan M. Metformin and vitamin B12 deficiency. Arch Intern Med 2002;162:484–485.
33. Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000;23:1227–1231.
34. Ovalle F, Ovalle-Berumen F. Thiazolidinediones: a review of their benefits and risks. South Med J2002;95:1188–1194.
35. Lebovitz H, Dole J, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280–288.
36. Parulkar A, Pendergrass M, Granda-Ayalar R, et al. Nonhypoglycemic effects of thiazolidinediones.Ann Intern Med 2001;134:61–71.
37. Lebovitz H. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18:S16–S22.
38. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118–121.
39. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000;132:121–124.
40. Maeda K. Hepatocellular injury in a patient receiving pioglitazone [Letter]. Ann Intern Med2001;135:306.
41. May L, Lefkowitch J, Kram M, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449–452.
42. Van Gaal L, Scheen A. Are all glitazones the same? Diabetes Metab Res Rev 2002;18:S1–S4.
43. Goldstein B. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18:S16–S22.
44. Miyazaki Y, Mahankali A, Matsuda M, et al. Effects of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784–2791.
